• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Bio-Imaging Technologies Revenues up 50%

Bio-Imaging Technologies Revenues up 50%

February 12, 2009
CenterWatch Staff

Bio-Imaging Technologies reported 50% revenue growth for 2008 following the March 2008 acquisition of Phoenix Data Systems (PDS). Full year 2008 service revenues increased to $56.2 million, up from $37.5 million in 2007. PDS accounted for $12.5 million of that revenue.

Service revenues for the fourth quarter also increased, up 48% to $15 million compared with $10.1 million for the same period in 2007. For the full year 2008, net income jumped 73.5% to $5.8 million, or $0.40 per fully diluted share, compared with net income for the full year 2007 of $3.3 million, or $0.26 per fully diluted share.

“With the acquisition and integration of PDS into our suite of clinical trial services, we are capitalizing on our strong relationships with major pharmaceutical, biotech and medical device companies,” said Bio-Imaging president and CEO Mark Weinstein.“We believe Bio-Imaging’s success, despite the global economic slowdown, demonstrates not only our strong business model, but also the important role our clinical trial services play as major pharmaceutical, biotech and medical device companies strive to get their products to market.”

The company maintained its full year 2009 service revenue guidance of $60 to $63 million, with fully diluted earnings per share to be in the range of $0.23 to $0.25, despite an 8.8% decrease in backlog over the end of the third quarter 2008.

“We continue to see our clients responding to current economic conditions with some contract decisions being delayed and certain major projects being split into smaller components from a budget approval process,” Weinstein said.

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing